Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
viernes, octubre 09
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
TransMedics Group Inc
TMDX
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$78.50
-0.50
-0.63%
Últ. Act.: Oct 9, 3:30 PM
$78.99
-0.01
-0.01%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
TransMedics Group Financials
TransMedics Group (TMDX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
TransMedics Group Appoints Fernando Araujo CFO, Effective Sept. 21; Reaffirms FY26 Revenue Range $737M - $757M
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for transplantation, today announced the appointment of Fernando Araujo as Chief Financial
Benzinga Newsdesk
PRO
TransMedics Group Raises FY2026 Sales Guidance from $727.000M-$757.000M to $737.000M-$757.000M vs $732.700M Est
TransMedics Group (NASDAQ:TMDX) raises FY2026 sales outlook from $727.000 million-$757.000 million to $737.000 million-$757.000 million vs $732.700 million estimate.
Benzinga Newsdesk
PRO
TransMedics Gr Q2 Adj. EPS $0.44 Misses $0.47 Estimate, Sales $189.948M Beat $183.635M Estimate
TransMedics Gr (NASDAQ:TMDX) reported quarterly earnings of $0.44 per share which missed the analyst consensus estimate of $0.47 by 6.38 percent. This is a 52.17 percent decrease over earnings of $0.92 per share from
Benzinga Newsdesk
PRO
TransMedics Group Affirms FY2026 Sales Guidance of $727.000M-$757.000M vs $737.825M Est
TransMedics Group (NASDAQ:TMDX) affirms FY2026 sales outlook from $727.000 million-$757.000 million to $727.000 million-$757.000 million vs $737.825 million estimate.
Benzinga Newsdesk
PRO
TransMedics Gr Q1 Adj. EPS $0.30 Misses $0.61 Estimate, Sales $173.933M Beat $172.636M Estimate
TransMedics Gr (NASDAQ:TMDX) reported quarterly earnings of $0.30 per share which missed the analyst consensus estimate of $0.61 by 50.82 percent. This is a 59.46 percent decrease over earnings of $0.74 per share from
Benzinga Newsdesk
Earnings Scheduled For May 5, 2026
Benzinga Insights
